Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
1.
World J Urol ; 37(1): 3-13, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30105454

RESUMEN

PURPOSE: To update current recommendations on prevention, screening, diagnosis, and evaluation of bladder cancer (BC) based on a thorough assessment of the most recent literature on these topics. METHODS: A non-systematic review was performed, including articles until June 2017. A variety of original articles, reviews, and editorials were selected according to their epidemiologic, demographic, and clinical relevance. Assessment of the level of evidence and grade of recommendations was performed according to the International Consultation on Urological Diseases grading system. RESULTS: BC is the ninth most common cancer worldwide with 430,000 new cases in 2012. Currently, approximately 165,000 people die from the disease annually. Absolute incidence and prevalence of BC are expected to rise significantly during the next decades because of population ageing. Tobacco smoking is still the main risk factor, accounting for about 50% of cases. Smoking cessation is, therefore, the most relevant recommendation in terms of prevention, as the risk of developing BC drops almost 40% within 5 years of cessation. BC screening is not recommended for the general population. BC diagnosis remains mainly based on cystoscopy, but development of new endoscopic and imaging technologies may rapidly change the diagnosis algorithm. The same applies for local, regional, and distant staging modalities. CONCLUSIONS: A thorough understanding of epidemiology, risk factors, early detection strategies, diagnosis, and evaluation is essential for correct, evidence-based management of BC patients. Recent developments in endoscopic techniques and imaging raise the hope for providing better risk-adopted approaches and thereby improving clinical outcomes.


Asunto(s)
Carcinoma de Células Transicionales/epidemiología , Cistoscopía , Dinámica Poblacional , Cese del Hábito de Fumar , Fumar Tabaco/epidemiología , Neoplasias de la Vejiga Urinaria/epidemiología , Algoritmos , Carcinoma de Células Transicionales/diagnóstico , Carcinoma de Células Transicionales/patología , Carcinoma de Células Transicionales/prevención & control , Detección Precoz del Cáncer , Humanos , Incidencia , Imagen por Resonancia Magnética , Imagen de Banda Estrecha , Estadificación de Neoplasias , Guías de Práctica Clínica como Asunto , Prevalencia , Factores de Riesgo , Sociedades Médicas , Tomografía Computarizada por Rayos X , Neoplasias de la Vejiga Urinaria/diagnóstico , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/prevención & control , Urología
2.
Int. braz. j. urol ; 43(4): 607-614, July-Aug. 2017. tab
Artículo en Inglés | LILACS | ID: biblio-892866

RESUMEN

ABSTRACT Objectives Smoking is the most important risk factor for bladder cancer and smoking cessation is associated with reduced risk of tumor recurrence and progression. The aim of this study is to assess the awareness of non-muscle invasive bladder cancer (NMIBC) patients regarding the importance of smoking cessation, determine their access to smoking cessation programs and the effects of smoking cessation on recurrence rates of NMIBC. Materials and Methods NMIBC patients who were followed with cystoscopy were included in the study. Their demographic properties were recorded, along with their smoking habits, awareness regarding the effects of smoking on bladder cancer and previous attempts for smoking cessation. Moreover, the patients were asked whether they applied for a smoking cessation program. Recurrence of bladder cancer during the follow-up period was also noted. Results A total of 187 patients were included in the study. The mean age was 64.68±12.05 (range: 15-90) and the male to female ratio was 167/20. At the time of diagnosis, 114 patients (61.0%) were active smokers, 35 patients (18.7%) were ex-smokers and 38 patients (20.3%) had never smoked before. After the diagnosis, 83.3% of the actively smoking patients were advised to quit smoking and 57.9% of them quit smoking. At the time of the study, 46.52% of the NMIBC patients were aware of the link between smoking and bladder cancer, whereas only 4.1% of the smoking patients were referred to smoking cessation programs. After a mean follow-up of 32.28±11.42 months, 84 patients (44.91%) had recurrence; however, current smoking status or awareness of the causative role of smoking on NMIBC did not affect the recurrence. Conclusion In our study group, the majority of the NMIBC patients were not aware of the association between smoking and bladder cancer. Although most of the physicians advised patients to quit smoking, a significant amount of the patients were still active smokers during follow-up. Only a small proportion of patients were referred to smoking cessation programs. Urologists should take a more active role in the battle against smoking and refer those patients to smoking cessation programs. Larger study populations with longer follow-up periods are needed to better demonstrate the beneficial effects of smoking cessation on recurrence rates.


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Adulto Joven , Neoplasias de la Vejiga Urinaria/etiología , Fumar/efectos adversos , Cese del Hábito de Fumar , Factores Socioeconómicos , Neoplasias de la Vejiga Urinaria/prevención & control , Conocimientos, Actitudes y Práctica en Salud , Factores de Riesgo , Estudios de Seguimiento , Progresión de la Enfermedad , Persona de Mediana Edad , Recurrencia Local de Neoplasia
3.
Int Braz J Urol ; 43(4): 607-614, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28537702

RESUMEN

OBJECTIVES: Smoking is the most important risk factor for bladder cancer and smoking cessation is associated with reduced risk of tumor recurrence and progression. The aim of this study is to assess the awareness of non-muscle invasive bladder cancer (NMIBC) patients regarding the importance of smoking cessation, determine their access to smoking cessation programs and the effects of smoking cessation on recurrence rates of NMIBC. MATERIALS AND METHODS: NMIBC patients who were followed with cystoscopy were included in the study. Their demographic properties were recorded, along with their smoking habits, awareness regarding the effects of smoking on bladder cancer and previous attempts for smoking cessation. Moreover, the patients were asked whether they applied for a smoking cessation program. Recurrence of bladder cancer during the follow-up period was also noted. RESULTS: A total of 187 patients were included in the study. The mean age was 64.68±12.05 (range: 15-90) and the male to female ratio was 167/20. At the time of diagnosis, 114 patients (61.0%) were active smokers, 35 patients (18.7%) were ex-smokers and 38 patients (20.3%) had never smoked before. After the diagnosis, 83.3% of the actively smoking patients were advised to quit smoking and 57.9% of them quit smoking. At the time of the study, 46.52% of the NMIBC patients were aware of the link between smoking and bladder cancer, whereas only 4.1% of the smoking patients were referred to smoking cessation programs. After a mean follow-up of 32.28±11.42 months, 84 patients (44.91%) had recurrence; however, current smoking status or awareness of the causative role of smoking on NMIBC did not affect the recurrence. CONCLUSION: In our study group, the majority of the NMIBC patients were not aware of the association between smoking and bladder cancer. Although most of the physicians advised patients to quit smoking, a significant amount of the patients were still active smokers during follow-up. Only a small proportion of patients were referred to smoking cessation programs. Urologists should take a more active role in the battle against smoking and refer those patients to smoking cessation programs. Larger study populations with longer follow-up periods are needed to better demonstrate the beneficial effects of smoking cessation on recurrence rates.


Asunto(s)
Cese del Hábito de Fumar , Fumar/efectos adversos , Neoplasias de la Vejiga Urinaria/etiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Conocimientos, Actitudes y Práctica en Salud , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Factores de Riesgo , Factores Socioeconómicos , Neoplasias de la Vejiga Urinaria/prevención & control , Adulto Joven
4.
Urol Oncol ; 35(3): 113.e1-113.e7, 2017 03.
Artículo en Inglés | MEDLINE | ID: mdl-27884539

RESUMEN

To determine the use of prophylactic intravesical chemotherapy (pIVC) following radical nephroureterectomy (RNU) and barriers to utilization in a survey study of urologic oncologists. METHODS: A survey instrument was constructed, which queried respondents on professional experience, practice environment, pIVC use, and reasons for not recommending pIVC when applicable. The survey was electronically distributed to members of the Society of Urologic Oncology over an 8-week period. Survey software was used for analysis. RESULTS: The survey response rate was 22% (158 of 722). Half of the respondents were in practice for ≤10 years, while 90% performed ≤10 RNU cases annually. Of the 144 urologists regularly performing RNU, only 51% reported administering pIVC, including 22 exclusively in patients with a prior history of bladder cancer. One-third administered pIVC intraoperatively, whereas the remainder instilled pIVC at ≤3 (7%), 4 to 7 (37%), 8 to 14 (20%), and>14 (3%) days postoperatively. Almost all urologists noted giving a single instillation of pIVC. Agents included mitomycin-C (88%), thiotepa (7%), doxorubicin (3%), epirubicin (1%), and BCG (1%). Among respondents who did not administer pIVC, the most common reasons cited included lack of data supporting use (44%), personal preference (19%), and office infrastructure (17%). CONCLUSION: Only 51% of urologic oncologists report using pIVC in patients undergoing RNU. Reasons underlying this underutilization are multifactorial, thereby underscoring the need for continued dissemination of existing data and additional studies to support its benefits. Moreover, improving the logistics of pIVC administration may help to increase utilization rates.


Asunto(s)
Antineoplásicos/uso terapéutico , Vacuna BCG/uso terapéutico , Carcinoma de Células Transicionales/tratamiento farmacológico , Neoplasias Renales/tratamiento farmacológico , Recurrencia Local de Neoplasia/prevención & control , Neoplasias Ureterales/tratamiento farmacológico , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Administración Intravesical , Carcinoma de Células Transicionales/cirugía , Quimioterapia Adyuvante/métodos , Quimioterapia Adyuvante/estadística & datos numéricos , Doxorrubicina/uso terapéutico , Epirrubicina/uso terapéutico , Humanos , Instilación de Medicamentos , Neoplasias Renales/cirugía , Mitomicina/uso terapéutico , Nefroureterectomía , Oncólogos , Atención Perioperativa/métodos , Estudios Retrospectivos , Encuestas y Cuestionarios , Tiotepa/uso terapéutico , Neoplasias Ureterales/cirugía , Neoplasias de la Vejiga Urinaria/prevención & control , Neoplasias de la Vejiga Urinaria/cirugía
5.
Acta Cir Bras ; 29(7): 423-8, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25054872

RESUMEN

PURPOSE: To evaluate the genotoxicity of propolis and L-lysine, as well as their effects on the possible cellular damage in erythroblasts (bone marrow) and leukocytes (peripheral blood) caused by the carcinogen BBN (n - butyl - n {4 - hydroxybutyl} nitrosamine) in rats subjected to bladder carcinogenesis and treated with green propolis and L-lysine. METHODS: One hundred and twenty five rats were distributed into the following groups: I, IIA, IIB, III, K, L M N, X, XI, XII and XIII. Groups I to X received BBN in drinking water for 14 weeks (wks). Group I was treated with intragastric (ig) propolis at 150 mg/kg body weight, for 44 wks, beginning 30 days before start of BBN. Groups IIA and III were treated with propolis (150 mg/kg), for 40 wks, subcutaneous (sc) and ig, respectively, beginning simultaneously with BBN. On the 32nd wk, the animals of groups L, M and N were treated ig with L-lysine (300 mg/kg), celecoxib (30 mg/kg) and propolis (300 mg/kg), respectively, up to the 40th wk. The groups that received only BBN (IIB and K) were treated with water, sc and orally, respectively, for 40 wks. Groups XI, XII and XIII received respectively propolis (150 mg/kg), L-lysine (150 mg/kg) and water ig for 40 wks. After 40 wks, the surviving animals were anesthetized and subjected to femoral bone marrow aspiration and blood collection from the aorta, for CA and MNT, respectively, for investigation of genotoxicity. RESULTS: Groups IIB and K, which received only BBN and water, showed the greatest DNA damage in peripheral leukocytes (CA) and largest number of micronuclei in bone marrow erythrocytes (MNT) in relation to all other groups that received BBN and lysine and/or propolis (p<0.001). CONCLUSIONS: Both propolis and L-lysine are effective in protecting against genotoxicity, as well not being genotoxic themselves toward the cells evaluated, at the doses and times administered and according to the two tests utilized.


Asunto(s)
Células de la Médula Ósea/efectos de los fármacos , Carcinogénesis/efectos de los fármacos , Linfocitos/efectos de los fármacos , Lisina/farmacología , Própolis/farmacología , Pirazoles/farmacología , Sulfonamidas/farmacología , Animales , Anticarcinógenos/farmacología , Pruebas de Carcinogenicidad , Celecoxib , Ensayo Cometa , Daño del ADN , Pruebas de Micronúcleos , Ratas Wistar , Valores de Referencia , Reproducibilidad de los Resultados , Factores de Tiempo , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/prevención & control
6.
Acta cir. bras ; Acta cir. bras;29(7): 423-428, 07/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-714578

RESUMEN

PURPOSE: To evaluate the genotoxicity of propolis and L-lysine, as well as their effects on the possible cellular damage in erythroblasts (bone marrow) and leukocytes (peripheral blood) caused by the carcinogen BBN (n - butyl - n {4 - hydroxybutyl} nitrosamine) in rats subjected to bladder carcinogenesis and treated with green propolis and L-lysine. METHODS: One hundred and twenty five rats were distributed into the following groups: I, IIA, IIB, III, K, L M N, X, XI, XII and XIII. Groups I to X received BBN in drinking water for 14 weeks (wks). Group I was treated with intragastric (ig) propolis at 150 mg/kg body weight, for 44 wks, beginning 30 days before start of BBN. Groups IIA and III were treated with propolis (150 mg/kg), for 40 wks, subcutaneous (sc) and ig, respectively, beginning simultaneously with BBN. On the 32nd wk, the animals of groups L, M and N were treated ig with L-lysine (300 mg/kg), celecoxib (30 mg/kg) and propolis (300 mg/kg), respectively, up to the 40th wk. The groups that received only BBN (IIB and K) were treated with water, sc and orally, respectively, for 40 wks. Groups XI, XII and XIII received respectively propolis (150 mg/kg), L-lysine (150 mg/kg) and water ig for 40 wks. After 40 wks, the surviving animals were anesthetized and subjected to femoral bone marrow aspiration and blood collection from the aorta, for CA and MNT, respectively, for investigation of genotoxicity. RESULTS: Groups IIB and K, which received only BBN and water, showed the greatest DNA damage in peripheral leukocytes (CA) and largest number of micronuclei in bone marrow erythrocytes (MNT) in relation to all other groups that received BBN and lysine and/or propolis (p<0.001). CONCLUSIONS: Both propolis and L-lysine are effective in protecting against genotoxicity, as well not being genotoxic themselves toward the cells evaluated, at the doses and times administered and according to the two tests utilized. .


Asunto(s)
Animales , Células de la Médula Ósea/efectos de los fármacos , Carcinogénesis/efectos de los fármacos , Linfocitos/efectos de los fármacos , Lisina/farmacología , Própolis/farmacología , Pirazoles/farmacología , Sulfonamidas/farmacología , Anticarcinógenos/farmacología , Pruebas de Carcinogenicidad , Ensayo Cometa , Daño del ADN , Pruebas de Micronúcleos , Ratas Wistar , Valores de Referencia , Reproducibilidad de los Resultados , Factores de Tiempo , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/prevención & control
7.
Plant Foods Hum Nutr ; 67(3): 235-41, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22961050

RESUMEN

Açai, fruit from Euterpe oleraceae Martius, is consumed in natura and in a variety of beverages and food preparations and possesses several potential antioxidant compounds. In a first study for anticarcinogenicity screening, male Swiss mice (n = 20/per group) were chemically-induced to urothelial bladder carcinogenesis for 10 weeks and received a standard diet or a standard diet containing 2.5 and 5 % spray-dried açai pulp (AP) for 10 weeks. At week 20, the incidence of simple and nodular hyperplasia and the incidence and multiplicity of transitional cell carcinoma (TCC) were evaluated. In a second study for antigenotoxicity screening, male Swiss mice (n = 6/per group) were fed standard diet or standard diet containing 5 % AP for three weeks. Urothelial cell suspensions were obtained and challenged with H(2)O(2) for induction of DNA damage and analyzed by comet assay. Overall, dietary 5 % AP reduced TCC incidence and multiplicity (p = 0.019 and p = 0.015, respectively) and tumor cell proliferation and p63 expression (p = 0.02 and p = 0.007, respectively), Furthermore, the group fed the 5 % AP presented a significant reduction (p < 0.01) in DNA damage induced by H(2)O(2), a notable oxidant agent. The results suggest that the spray-dried açai pulp used here inhibits the TCC development in male Swiss mice, probably due to its potential antioxidant action.


Asunto(s)
Arecaceae , Carcinoma de Células Transicionales/prevención & control , Dieta , Frutas , Fitoterapia , Neoplasias de la Vejiga Urinaria/prevención & control , Vejiga Urinaria/efectos de los fármacos , Animales , Anticarcinógenos/farmacología , Anticarcinógenos/uso terapéutico , Antineoplásicos Fitogénicos/farmacología , Antineoplásicos Fitogénicos/uso terapéutico , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Carcinoma de Células Transicionales/metabolismo , Proliferación Celular/efectos de los fármacos , Ensayo Cometa , Daño del ADN/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Peróxido de Hidrógeno , Hiperplasia , Masculino , Ratones , Ratones Endogámicos , Fosfoproteínas/metabolismo , Preparaciones de Plantas/farmacología , Preparaciones de Plantas/uso terapéutico , Transactivadores/metabolismo , Vejiga Urinaria/citología , Vejiga Urinaria/metabolismo , Neoplasias de la Vejiga Urinaria/inducido químicamente , Neoplasias de la Vejiga Urinaria/metabolismo
8.
Maturitas ; 72(1): 72-8, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22386766

RESUMEN

BACKGROUND: Over 6 million people die annually in the world because of cancer. Several groups are focused on studying cancer chemoprevention approaches. Resveratrol, a polyphenol, at high dosages, has been reported as antitumor and chemopreventive. However, it has a dose-dependent effect on cell death, even on some cancer cells. OBJECTIVES: Our aim was to investigate this dose-dependent effect on human bladder carcinoma ECV304 cells during oxidative stress condition. METHODS: For this purpose, ECV304 cells incubated with different Resveratrol concentrations were analyzed as for their metabolic rate, membrane permeability, DNA fragmentation, anti/proapoptotic protein levels and phosphatidylserine exposure after oxidative stress. RESULTS: Resveratrol induced cell death at high concentrations (>20 µM), but not at low ones (0.1-20 µM). Pretreatment with 2.5 µM protected the cells from oxidative damage, whereas 50 µM intensified the cell death and significantly increased Bad/Bcl-2 ratio (proapoptotic/antiapoptotic proteins). Resveratrol was able to modulate NO and PGE(2) secretion and performed an anti-adhesion activity of neutrophils on PMA-activated ECV304 cells. CONCLUSIONS: Resveratrol at high doses induces cell death of ECV304 cells whereas low doses induce protection. Modulation of Bcl-2 protein induced by Resveratrol could be mediating this effect. This information about the role of Resveratrol on cancer alerts us about its dose-dependent effects and could lead the design of future chemoprevention strategies.


Asunto(s)
Antineoplásicos Fitogénicos/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Fitoterapia , Extractos Vegetales/uso terapéutico , Estilbenos/uso terapéutico , Neoplasias de la Vejiga Urinaria/prevención & control , Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Dinoprostona/metabolismo , Relación Dosis-Respuesta a Droga , Humanos , Neutrófilos/efectos de los fármacos , Óxido Nítrico/metabolismo , Extractos Vegetales/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Resveratrol , Estilbenos/farmacología , Acetato de Tetradecanoilforbol , Neoplasias de la Vejiga Urinaria/metabolismo , Proteína Letal Asociada a bcl/metabolismo
9.
Acta Cir Bras ; 27(2): 185-92, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22378376

RESUMEN

PURPOSE: To determine the effects of green propolis extracted in L-lysine (WSDP) and of L- lysine for 40 weeks on induced rat bladder carcinogenesis. METHODS: The animals (groups I, II, III, IV, V and VI) received BBN during 14 weeks. Group I was treated with propolis 30 days prior received BBN, and then these animals were treated daily with propolis; Groups II and III was treated with subcutaneous and oral propolis (respectively) concurrently with BBN. The animals of Group IV were treated L-lysine; Group V received water subcutaneous; and Group VI received only to BBN. Among the animals not submitted to carcinogenesis induction, Group VII received propolis, Group VIII received L-lysine and Group IX received water. RESULTS: The carcinoma incidence in Group I was lower than that of control (Group VI). The carcinoma multiplicity in Group IV was greater than in Group VI. All animals treated with L-lysine developed carcinomas, and they were also more invasive in Group IV than in controls. On the other hand, Group VIII showed no bladder lesions. CONCLUSION: The WSDP is chemopreventive against rat bladder carcinogenesis, if administered 30 days prior to BBN , and that L-lysine causes promotion of bladder carcinogenesis.


Asunto(s)
Butilhidroxibutilnitrosamina/uso terapéutico , Lisina/farmacología , Extractos Vegetales/uso terapéutico , Própolis/uso terapéutico , Neoplasias de la Vejiga Urinaria/prevención & control , Animales , Anticarcinógenos/farmacología , Anticarcinógenos/uso terapéutico , Carcinógenos , Femenino , Extractos Vegetales/farmacología , Própolis/farmacología , Ratas , Ratas Wistar , Factores de Tiempo , Resultado del Tratamiento , Neoplasias de la Vejiga Urinaria/inducido químicamente , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Neoplasias de la Vejiga Urinaria/patología
10.
Acta cir. bras ; Acta cir. bras;27(2): 185-192, Feb. 2012. ilus, tab
Artículo en Inglés | LILACS | ID: lil-614540

RESUMEN

PURPOSE: To determine the effects of green propolis extracted in L-lysine (WSDP) and of L- lysine for 40 weeks on induced rat bladder carcinogenesis. METHODS: The animals (groups I, II, III, IV, V and VI) received BBN during 14 weeks. Group I was treated with propolis 30 days prior received BBN, and then these animals were treated daily with propolis; Groups II and III was treated with subcutaneous and oral propolis (respectively) concurrently with BBN. The animals of Group IV were treated L-lysine; Group V received water subcutaneous; and Group VI received only to BBN. Among the animals not submitted to carcinogenesis induction, Group VII received propolis, Group VIII received L-lysine and Group IX received water. RESULTS: The carcinoma incidence in Group I was lower than that of control (Group VI). The carcinoma multiplicity in Group IV was greater than in Group VI. All animals treated with L-lysine developed carcinomas, and they were also more invasive in Group IV than in controls. On the other hand, Group VIII showed no bladder lesions. CONCLUSION: The WSDP is chemopreventive against rat bladder carcinogenesis, if administered 30 days prior to BBN , and that L-lysine causes promotion of bladder carcinogenesis.


OBJETIVO: Determinar os efeitos da própolis verde extraída em L - Lisina (WSDP) e da L-Lisina por 40 semanas em ratos induzidos a carcinogênese de bexiga. MÉTODOS: Os animais (grupos I, II, III, IV, V e VI) receberam BBN por 14 semanas. O grupo I foi tratado com própolis 30 dias antes de receber BBN e em seguida estes animais foram tratados diariamente com própolis; Os grupos II e III foram tratados com própolis subcutânea e oral (respectivamente) e concorretemente com BBN. Os animais do grupo IV foram tratados com L- Lisina; o grupo V recebeu água subcutânea; o grupo VI recebeu apenas BBN. Entre os animais não submetidos a indução de carcinogênese, Grupo VII, receberam própolis, Grupo VIII, receberam L-Lisina e Grupo IX receberam água. RESULTADOS: A incidência de carcinoma no grupo I foi menor que no grupo controle (grupo IV) A multiplicidade de carcinoma no grupo IV foi maior que no grupo VI. Todos os animais tratados com L - Lisina desenvolveram carcinomas e estes foram mais invasivos no grupo IV que no grupo controle. Por outro lado o grupo VIII não apresentou lesões. CONCLUSÃO: WSDP é quimiopreventiva contra a carcinogese de bexiga se administrada 30 dias antes do início do BBN, e a L - Lisina causa promoção da carcinogênese de bexiga.


Asunto(s)
Animales , Femenino , Ratas , Butilhidroxibutilnitrosamina/uso terapéutico , Lisina/farmacología , Extractos Vegetales/uso terapéutico , Própolis/uso terapéutico , Neoplasias de la Vejiga Urinaria/prevención & control , Anticarcinógenos/farmacología , Anticarcinógenos/uso terapéutico , Carcinógenos , Extractos Vegetales/farmacología , Própolis/farmacología , Ratas Wistar , Factores de Tiempo , Resultado del Tratamiento , Neoplasias de la Vejiga Urinaria/inducido químicamente , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Neoplasias de la Vejiga Urinaria/patología
11.
Acta cir. bras. ; 27(2): 185-192, 2012. ilus, tab
Artículo en Inglés | VETINDEX | ID: vti-4080

RESUMEN

PURPOSE: To determine the effects of green propolis extracted in L-lysine (WSDP) and of L- lysine for 40 weeks on induced rat bladder carcinogenesis. METHODS: The animals (groups I, II, III, IV, V and VI) received BBN during 14 weeks. Group I was treated with propolis 30 days prior received BBN, and then these animals were treated daily with propolis; Groups II and III was treated with subcutaneous and oral propolis (respectively) concurrently with BBN. The animals of Group IV were treated L-lysine; Group V received water subcutaneous; and Group VI received only to BBN. Among the animals not submitted to carcinogenesis induction, Group VII received propolis, Group VIII received L-lysine and Group IX received water. RESULTS: The carcinoma incidence in Group I was lower than that of control (Group VI). The carcinoma multiplicity in Group IV was greater than in Group VI. All animals treated with L-lysine developed carcinomas, and they were also more invasive in Group IV than in controls. On the other hand, Group VIII showed no bladder lesions. CONCLUSION: The WSDP is chemopreventive against rat bladder carcinogenesis, if administered 30 days prior to BBN , and that L-lysine causes promotion of bladder carcinogenesis.(AU)


OBJETIVO: Determinar os efeitos da própolis verde extraída em L - Lisina (WSDP) e da L-Lisina por 40 semanas em ratos induzidos a carcinogênese de bexiga. MÉTODOS: Os animais (grupos I, II, III, IV, V e VI) receberam BBN por 14 semanas. O grupo I foi tratado com própolis 30 dias antes de receber BBN e em seguida estes animais foram tratados diariamente com própolis; Os grupos II e III foram tratados com própolis subcutânea e oral (respectivamente) e concorretemente com BBN. Os animais do grupo IV foram tratados com L- Lisina; o grupo V recebeu água subcutânea; o grupo VI recebeu apenas BBN. Entre os animais não submetidos a indução de carcinogênese, Grupo VII, receberam própolis, Grupo VIII, receberam L-Lisina e Grupo IX receberam água. RESULTADOS: A incidência de carcinoma no grupo I foi menor que no grupo controle (grupo IV) A multiplicidade de carcinoma no grupo IV foi maior que no grupo VI. Todos os animais tratados com L - Lisina desenvolveram carcinomas e estes foram mais invasivos no grupo IV que no grupo controle. Por outro lado o grupo VIII não apresentou lesões. CONCLUSÃO: WSDP é quimiopreventiva contra a carcinogese de bexiga se administrada 30 dias antes do início do BBN, e a L - Lisina causa promoção da carcinogênese de bexiga.(AU)


Asunto(s)
Animales , Femenino , Ratas , Butilhidroxibutilnitrosamina/uso terapéutico , Lisina/farmacología , Extractos Vegetales/uso terapéutico , Própolis/uso terapéutico , Neoplasias de la Vejiga Urinaria/prevención & control , Anticarcinógenos/farmacología , Anticarcinógenos/uso terapéutico , Carcinógenos , Extractos Vegetales/farmacología , Própolis/farmacología , Ratas Wistar , Factores de Tiempo , Resultado del Tratamiento , Neoplasias de la Vejiga Urinaria/inducido químicamente , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Neoplasias de la Vejiga Urinaria/patología
12.
Córdoba; s.n; 2010. [19],96 p. ilus. (125272).
Tesis en Español | BINACIS | ID: bin-125272

RESUMEN

Introducción y objetivo: En Argentina, el cáncer de vejiga ocupa el séptimo lugar entre las causas de muerte por cáncer en varones e investigaciones recientes muestran que los Tumores de Vías Urinarias (TVU) constituyen el cuarto tipo de neoplasia más frecuente en la provincia de Córdoba. Numerosos estudios han encontrado que los factores dietarios se relacionan con el riesgo de desarrollar TVU. Estos trabajos se han focalizado, en general, en alimentos aislados y en algunos nutrientes y han analizado el riesgo mediante metodologías tradicionales. De esta manera, solo se han logrado inferencias parciales. Un nuevo enfoque, basado en el análisis de los patrones alimentarios en asociación al riesgo, puede contribuir a una mejor comprensión de la carcinogénesis de vías urinarias. En consecuencia, el objetivo de este estudio de casos y controles, realizado en Córdoba entre 2004 y 2008, fue establecer la relación entre el desarrollo de TVU y el consumo de alimentos que configuran el patrón cultural de esta población. Materiales y Métodos: Se entrevistaron 168 pacientes con TVU, de la variedad transicional, istopatológicamente confirmados, y 334 controles sanos provenientes de los mismos hospitales y clínicas. Todos ellos fueron encuestados y se recabaron datos acerca de su alimentación habitual y su exposición a otros posibles factores de riesgo. Para explorar los patrones alimentarios se utilizó análisis de correspondencia múltiple y para establecer el riesgo se calcularon odds ratios - ajustados por edad, sexo, estado nutricional, estrato social, exposición ocupacional a sustancias con posible efecto mutagénico, hábito de fumar y actividad física ¹ e intervalos de confianza del 95% con regresión logística múltiple. Resultados: Se identificaron dos patrones alimentarios principales: el denominado patrón occidental se asoció con los casos de TVU, en tanto que el patrón prudente, con los controles...(AU)


Introduction: Bladder cancer is the 7th most frequent cause of death for males in Argentina and recent studies showed that urinary tract tumors (UTT) are the 4th most common among men in the province of Córdoba. A growing number of studies have shown that usual diet isassociated with the risk of developing UTT. These researches have focused mainly on single foods and nutrients, followed by traditional methods of analysis. Hence, only partialexplanations have been proposed. Thus, establishing food patterns could lead to further understanding of epigenetic factors on bladder tumor risks. The purpose of this case-control study, conducted in Cordoba between 2004 and 2008 was to describe the role of food patterns and to investigate any correlation with the risk of developing UTT. Materials and Methods: 168 patients with histologically confirmed transitional UTT and 334 healthycontrols from the same hospitals were studied. All subjects were interviewed about their food habits and their exposure to a number of known or suspected risk factors for UTT. Multiplecorrespondence analysis was used to explore food patterns and data analysis was performed by calculating Odds Ratios and their 95% confidence intervals by using Multiple LogisticRegression...(AU)


Asunto(s)
Humanos , Masculino , Femenino , Guías Alimentarias , Conducta Alimentaria , Conducta Alimentaria/fisiología , Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria , Neoplasias de la Vejiga Urinaria/prevención & control , Educación Alimentaria y Nutricional , Trastornos de Alimentación y de la Ingestión de Alimentos/complicaciones , Argentina
13.
Córdoba; s.n; 2010. [19],96 p. ilus.
Tesis en Español | LILACS | ID: lil-589541

RESUMEN

Introducción y objetivo: En Argentina, el cáncer de vejiga ocupa el séptimo lugar entre las causas de muerte por cáncer en varones e investigaciones recientes muestran que los Tumores de Vías Urinarias (TVU) constituyen el cuarto tipo de neoplasia más frecuente en la provincia de Córdoba. Numerosos estudios han encontrado que los factores dietarios se relacionan con el riesgo de desarrollar TVU. Estos trabajos se han focalizado, en general, en alimentos aislados y en algunos nutrientes y han analizado el riesgo mediante metodologías tradicionales. De esta manera, solo se han logrado inferencias parciales. Un nuevo enfoque, basado en el análisis de los patrones alimentarios en asociación al riesgo, puede contribuir a una mejor comprensión de la carcinogénesis de vías urinarias. En consecuencia, el objetivo de este estudio de casos y controles, realizado en Córdoba entre 2004 y 2008, fue establecer la relación entre el desarrollo de TVU y el consumo de alimentos que configuran el patrón cultural de esta población. Materiales y Métodos: Se entrevistaron 168 pacientes con TVU, de la variedad transicional, istopatológicamente confirmados, y 334 controles sanos provenientes de los mismos hospitales y clínicas. Todos ellos fueron encuestados y se recabaron datos acerca de su alimentación habitual y su exposición a otros posibles factores de riesgo. Para explorar los patrones alimentarios se utilizó análisis de correspondencia múltiple y para establecer el riesgo se calcularon odds ratios - ajustados por edad, sexo, estado nutricional, estrato social, exposición ocupacional a sustancias con posible efecto mutagénico, hábito de fumar y actividad física – e intervalos de confianza del 95% con regresión logística múltiple. Resultados: Se identificaron dos patrones alimentarios principales: el denominado patrón occidental se asoció con los casos de TVU, en tanto que el patrón prudente, con los controles...


Introduction: Bladder cancer is the 7th most frequent cause of death for males in Argentina and recent studies showed that urinary tract tumors (UTT) are the 4th most common among men in the province of Córdoba. A growing number of studies have shown that usual diet isassociated with the risk of developing UTT. These researches have focused mainly on single foods and nutrients, followed by traditional methods of analysis. Hence, only partialexplanations have been proposed. Thus, establishing food patterns could lead to further understanding of epigenetic factors on bladder tumor risks. The purpose of this case-control study, conducted in Cordoba between 2004 and 2008 was to describe the role of food patterns and to investigate any correlation with the risk of developing UTT. Materials and Methods: 168 patients with histologically confirmed transitional UTT and 334 healthycontrols from the same hospitals were studied. All subjects were interviewed about their food habits and their exposure to a number of known or suspected risk factors for UTT. Multiplecorrespondence analysis was used to explore food patterns and data analysis was performed by calculating Odds Ratios and their 95% confidence intervals by using Multiple LogisticRegression...


Asunto(s)
Humanos , Masculino , Femenino , Conducta Alimentaria/fisiología , Trastornos de Alimentación y de la Ingestión de Alimentos/complicaciones , Conducta Alimentaria , Educación Alimentaria y Nutricional , Guías Alimentarias , Neoplasias de la Vejiga Urinaria/prevención & control , Neoplasias de la Vejiga Urinaria , Vejiga Urinaria/patología , Argentina
14.
World J Urol ; 24(5): 591-6, 2006 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17021826

RESUMEN

The modifying potential of ginger on the development of preneoplasia and tumors in the male Wistar rat urinary bladder was investigated in a 36-week-long initiation-promotion assay for chemical carcinogenesis. Groups G1 to G3 were given 0.05% N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) in drinking water for 5 weeks and a 3% uracil meal for the subsequent 3 weeks. Groups G4 and G5 were treated with 3% uracil only for the same period. After these steps, groups G2, and G3 and G4 were fed for 26 weeks a ginger extract mixed at 0.5 and 1.0% in a basal diet, respectively. Thirty six weeks after the beginning of the experiment all rats were killed. The multiplicity of urothelial lesions (hyperplasia and neoplasia) was significantly lower (P = 0.013) in group G3 than in groups G1 and G2. The results suggest that 1.0% ginger meal exerts a protective effect on the post-initiation stage of rat chemically-induced urothelial carcinogenesis.


Asunto(s)
Quimioprevención/métodos , Extractos Vegetales/uso terapéutico , Neoplasias de la Vejiga Urinaria/prevención & control , Zingiber officinale , Animales , Apoptosis/efectos de los fármacos , Butilhidroxibutilnitrosamina , Proliferación Celular/efectos de los fármacos , Transformación Celular Neoplásica/efectos de los fármacos , Transformación Celular Neoplásica/patología , Suplementos Dietéticos , Relación Dosis-Respuesta a Droga , Masculino , Extractos Vegetales/administración & dosificación , Extractos Vegetales/farmacología , Ratas , Ratas Wistar , Uracilo , Neoplasias de la Vejiga Urinaria/inducido químicamente , Neoplasias de la Vejiga Urinaria/patología
15.
Environ Mol Mutagen ; 47(8): 624-30, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16878317

RESUMEN

Extracts of the spice ginger (Zingiber officinale Roscoe) are rich in gingerols and shogaols, which exhibit antioxidant, anti-inflammatory, antifungal, antimycobacterial, and anticarcinogenic proprieties. The present study evaluated the chemoprotective effects of a ginger extract on the DNA damage and the development of bladder cancer induced by N-butyl-N-(4-hydroxibutyl) nitrosamine (BBN)/N-methyl-N-nitrosourea (MNU) in male Swiss mice. Groups G1-G3 were given 0.05% BBN in drinking water for 18 weeks and four i.p. injections of 30 mg/kg body weight MNU at 1, 3, 10, and 18 weeks. Group G4 and G5 received only the BBN or MNU treatments, respectively, and groups G6 and G7 were not treated with BBN or MNU. Additionally, Groups G2, G3, and G6 were fed diets containing 1, 2, and 2% ginger extract, respectively, while Groups G1, G4, G5, and G7 were fed basal diet. Samples of peripheral blood were collected during the experiment for genotoxicity analysis; blood collected 4 hr after each MNU dose was used for the analysis of DNA damage with the Comet assay (assay performed on leukocytes from all groups), while reticulocytes collected 24 hr after the last MNU treatment of Groups G5-G7 were used for the micronucleus assay. At the end of the experiment, the urinary bladder was removed, fixed, and prepared for histopathological, cell proliferation, and apoptosis evaluations. Ginger by itself was not genotoxic, and it did not alter the DNA damage levels induced by the BBN/MNU treatment during the course of the exposure. The incidence and multiplicity of simple and nodular hyperplasia and transitional cell carcinoma (TCC) were increased by the BBN/MNU treatment, but dietary ginger had no significant effect on these responses. However, in Group G2 (BBN/MNU/2% ginger-treated group), there was an increased incidence of Grade 2 TCC. The results suggest that ginger extract does not inhibit the development of BBN-induced mouse bladder tumors.


Asunto(s)
Anticarcinógenos/farmacología , Daño del ADN/efectos de los fármacos , Neoplasias Urológicas/prevención & control , Zingiber officinale , Animales , Butilhidroxibutilnitrosamina/toxicidad , Modelos Animales de Enfermedad , Masculino , Metilnitrosourea/toxicidad , Ratones , Invasividad Neoplásica , Extractos Vegetales/farmacología , Neoplasias de la Vejiga Urinaria/inducido químicamente , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/prevención & control
16.
Int J Mol Med ; 16(4): 565-71, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16142388

RESUMEN

Bacillus Calmette-Guérin (BCG) is considered to be one of the most effective treatments for superficial and in situ bladder cancer. However, either failure to respond initially or relapse within the first 5 years of treatment has been observed in some patients. As nitric oxide (NO) has been detected in the bladder of BCG-treated patients, we analyzed the role of endogenous NO generated after BCG treatments on human (T24) and murine (MB49 and MBT2) bladder tumor cells in the viability of tumor and immune cells, both in vitro and in vivo. In vitro inhibition of cancer cells after BCG treatment was evaluated by cell titer assay. NO production was determined as nitrite by Griess reagent. The death of immunocytes was evaluated by 51Cr release. Tumor histology with hematoxylin and eosin and Masson's trichrome staining was performed. BCG induced a direct inhibition of tumor cell growth in vitro, independently of NO levels. Besides, BCG-mediated NO production by tumor cells induced the death of spleen and peritoneal cells in syngeneic mice. The in vivo inhibition of NO synthase (NOS) activity by NG-nitro-L-arginine methyl ester in combination with BCG, improved tumor regression by generating a healing tissue. The increase of NO generated after BCG administration may induce the death of immunocytes. The in vivo inhibition of NO ameliorated immunotherapy with BCG by additional tumor growth inhibition. Our results suggested the possibility that the final outcome of patients with bladder tumors may improve by modulating NOS activity concomitantly with BCG therapy.


Asunto(s)
Vacuna BCG/farmacología , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico/antagonistas & inhibidores , Neoplasias de la Vejiga Urinaria/prevención & control , Animales , Vacuna BCG/administración & dosificación , Vacuna BCG/uso terapéutico , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Quimioterapia Combinada , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Femenino , Humanos , Inyecciones Intralesiones , Macrófagos Peritoneales/citología , Macrófagos Peritoneales/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , NG-Nitroarginina Metil Éster/uso terapéutico , Trasplante de Neoplasias , Neoplasias Experimentales/metabolismo , Neoplasias Experimentales/patología , Neoplasias Experimentales/prevención & control , Óxido Nítrico/biosíntesis , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico Sintasa/farmacología , Bazo/citología , Bazo/efectos de los fármacos , Factores de Tiempo , Resultado del Tratamiento , Neoplasias de la Vejiga Urinaria/metabolismo , Neoplasias de la Vejiga Urinaria/patología
17.
Actas Urol Esp ; 28(5): 350-3, 2004 May.
Artículo en Español | MEDLINE | ID: mdl-15264677

RESUMEN

UNLABELLED: In developed countries, the incidence of tuberculous is major, and the incidence of bladder cancer is minor. Above the base of the utility of the BCG in the prevention of the tuberculous and the use in the treatment and prevention of the recurrences of cancer, it's investigated the relation between the 2 pathology's. PATIENTS AND METHODS: We effected a study retrospective and prospective. It's revised the history's of 52 cases of bladder cancer, it's interview 100 persons, and interview medicals what to dedicate to treat patients whit tuberculous, above the existence before patient what had the 2 pathology's or before case vaccinate with BCG what to develop bladder cancer. It's a study effected in tree groups of patients, in a period of 14 year, between 1985-1999. RESULTS: First group: all the cases what development bladder of cancer none of them to vaccinate with BCG. Second group: all to vaccinate with BCG with prevention of lung tuberculous none of them development bladder of cancer in the course of mean of 32 year. Third group: none of the patients what to treat for tuberculous developed bladder of cancer. Never a medical interview observe case some what development the two pathology's, or patients what vaccinate with BCG what development bladder of cancer.


Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Vacuna BCG/uso terapéutico , Neoplasias de la Vejiga Urinaria/prevención & control , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA